|Table of Contents|

Clinical features and prognostic factors of elderly non-small cell lung cancer patients in real-life clinical practice

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 03
Page:
415-419
Research Field:
Publishing date:

Info

Title:
Clinical features and prognostic factors of elderly non-small cell lung cancer patients in real-life clinical practice
Author(s):
Zhang Yizhuo1; Zhang Wenxia2; Wang Lijuan2; Wei Hong2; Zhu Qifeng2
1.Department of Geriatrics；2.Department of Oncology，Heze Municiple Hospital，Shandong Heze 274000，China.
Keywords:
lung neoplasms; geriatrics; prognosis
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2019.03.014
Abstract:
Objective：To explore the clinical features and prognostic factors of elderly patients with non-small cell lung cancer in real-life.Methods：The clinical data of 742 patients with non-small cell lung cancer（NSCLC)who were discharged from our hospital from June 2015 to June 2017，including Oncology，Thoracic Surgery，Respiratory Department and Geriatric Department，were retrospectively analyzed.SPSS 17.0 software was used to carry out statistical analysis with K-M method and Log-rank method was used to evaluate survival difference.COX multivariate regression model was used to determine the prognostic factors of multiple variables.The test level was α=0.05.Gender，age，physical condition(ECOG)，clinical stage，pathological type，complication and treatment were studied respectively.Results：The gender ratio of male and female in elderly non-small cell lung cancer in our center was 3.7∶1.Univariate analysis showed that age，pathological type，ECOG，clinical stage，treatment style and complications were risk factors for prognosis，and multivariate analysis showed pathological type，ECOG，clinical stage,treatment style and complications were risk factors for prognosis.Conclusion：The male and female ratio of elderly patients with NSCLC in our center is slightly higher than that of young patients.Gender and age have no significant influence on survival，but adenosquamous carcinoma，high ECOG score，late clinical staging，multiple complications and palliative treatment are independent risk factors for poor prognosis.

References:

[1]Gao Y，Gao F，Ma JL，et al.Analysis of the characteristics and prognosis of advanced non-small-cell lung cancer in older patients［J］.Patient Prefer Adherence，2015，9：1189-1194.
[2]Su C，Zhou F，Shen J，et al.Treatment of elderly patients or patients who are performance status 2（PS2) with advanced non-small cell lung cancer without epidermal growth factor receptor（EGFR) mutations and anaplastic lymphoma kinase（ALK) translocations-still a daily challenge［J］.Eur J Cancer，2017，83：266-278.
[3]Chen WQ，Zheng RS，Baade PD，et al.Cancer statistics in China，2015［J］.CA Cancer J Clin，2016，66(2)：115-132.
[4]Wang Y，Gao GH，Ren SX,et al.Clinical analysis of 141 cases of elderly patients with lung cancer［J］.Journal of Clinical Pulmonary Medicine，2016,21(04)：622-625.［王勇，高广辉，任胜祥，等.老年肺癌141例临床分析［J］.临床肺科杂志，2016，21(04)：622-625.］
[5]Zhang SD，Deng YM，Feng WN,et al Clinical analysis of 200 cases of senile lung cancer［J］.Journal of Basic and Clinical Oncology，2017，30(01)：82-83.［张顺达，邓燕明，冯卫能，等.200例老年肺癌患者临床分析［J］.肿瘤基础与临床，2017，30(01)：82-83.］
[6]Asmis TR，Ding K，Seymour L，et al.Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer：A review of National Cancer Institute of Canada Clinical Trials Group trials［J］.J Clin Oncol，2008，26(1)：54-59.
[7]Zheng H，Tong L，Hu Y，et al.Prognostic factors in 408 elderly lung cancer patients more than 70 years old［J］.Chinese Journal of Lung Cancer，2011，14(6)：502-506.
[8]Yang M，Wang YF，Wu XM，et al.Clinical characteristics and prognosis in elderly patients with advanced non-small cell lung cancer［J］.Chinese Journal of Clinical Oncology and Rehabilitation，2013，20(06)：554-557.［杨敏，王延风，吴晓明，等.184例老年晚期非小细胞肺癌的临床特点及预后分析［J］.中国肿瘤临床与康复，2013，20(06)：554-557.］
[9]Koyi H，Hillerdal G，Andersson O，et al.Chemotherapy treatment of elderly patients（≥70 years) with non-small cell lung cancer：A seven-year retrospective study of real-life clinical practice at Karolinska University Hospital，Sweden［J］.Lung Cancer Int，2015，2015：317868.
[10]Zhang Wei，He Jianjun，Xu Jing,et al.Analysis of the clinicopathological features of 721 cases with NSCLC［J］.Modern Oncology，2016,24(15)：2393-2397.［张伟，何建军，许静，等.721例非小细胞肺癌临床病理学特征分析［J］.现代肿瘤医学，2016，24(15)：2393-2397.］
[11]Zhu ZS，Yan WH，Yang Z,et al.Prognosis of elderly patients with non-small cell lung cancer［J］.Practical Journal of Cancer，2014，29(08)：939-941.［朱中山，严文辉，杨洲，等.老年非小细胞肺癌患者的预后分析［J］.实用癌症杂志，2014，29(08)：939-941.］
[12]Zhang HW，Wang ZY，Tang YJ.Clinical analysis of adenos quamouscarcinoma of the lung［J］.Chinese Journal of Clinical Oncology and Rehabilitation，2002，9(05)：72-73，75.［张宏伟，王朝阳，汤义军.肺腺鳞癌的临床分析［J］.中国肿瘤临床与康复，2002，9(05)：72-73，75.］
[13]Zhao WJ，Wang X，Ma KW.Progress in lung adenosquamous carcinoma［J］.Chinese Journal of Oncology，2017，39(4)：241-244.［赵文君，王旭，马克威.肺腺鳞癌研究进展［J］.中华肿瘤杂志，2017，39(4)：241-244.］
[14]Losanno T，Gridelli C.Recent advances in targeted advanced lung cancer therapy in the elderly［J］.Expert Rev Anticancer Ther，2017，17(9)：787-797.
[15]Oken MM，Creech RH，Tormey DC，et al.Toxicity and response criteria of the Eastern Cooperative Oncology Group［J］.Am J Clin Oncol，1982，5(6)：649-655.
[16]Bi N，Liang J，Wang L.Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage Ⅲ NSCLC：A subgroup analysis for ECOG 2 patients would be of great interest'［J］.Ann Oncol，2017，28(12)：3101-3103.
[17]Driessen EJ，Aarts MJ，Bootsma GP，et al.Trends in treatment and relative survival among non-small cell lung cancer patients in the netherlands（1990-2014)：Disparities between younger and older patients［J］.Lung Cancer，2017，108：198-204.
[18]Wee E.How Should We Choose the best therapy for elderly patients with stage Ⅲ non-small-cell lung cancer［J］.J Clin Oncol，2017，35(25)：2860-2862.
[19]Yang YJ，Zhang YM，Li YZ，et al.A five year analysis of clinical characteristics among lung cancer patients complicated with type 2 diabetes mellitus in Tangshan［J］.Immunoassays and Clinical Medicine，2016,23(06)：633-636.［杨雅静，张玉敏，李玉柱，等.唐山2010～2014年肺癌合并2型糖尿病患者临床特征分析［J］.标记免疫分析与临床，2016，23(06)：633-636.］
[20]Guo XF，Li P.Analysis of radiation pneumonia in patients with non-small cell lung cancer and type 2 diabetes mellitus［J］.Practical Journal of Cancer，2016，31(05)：760-762.［郭小芳，李平.非小细胞肺癌合并2型糖尿病患者发生放射性肺炎的分析［J］.实用癌症杂志，2016，31(05)：760-762.］
[21]Liu J.Analysis of the correlation of the radiation pneumonia in the diabetic and stage Ⅲ non-small cell lung cancer［J］.Practical Journal of Cancer，2016，31(10)：1646-1647，1651.［刘珺.糖尿病与Ⅲ期非小细胞肺癌的放射性肺炎的相关性分析［J］.实用癌症杂志，2016，31(10)：1646-1647，1651.］
[22]Wang P，Zhang D，Guo XG,et al.Clinical characteristics and risk factors affecting outcomes of elderly patients with non-small cell lung cancer complicated by chronic obstructive pulmonary disease［J］.Journal of Southern Medical University，2017，37(07)：889-894.［王鹏，张东，郭学光，等.老年非小细胞肺癌合并慢性阻塞性肺病患者的临床特征［J］.南方医科大学学报，2017，37(07)：889-894.］
[23]Yu H，Qiu XG.The guidance significance of the comprehensive evaluation system on the individualized treatment of senile non-small cell lung cancer patients［J］.Chinese Journal of Gerontology，2015，35(02)：387-389.［余虹，邱昕光.老年综合评价体系对老年非小细胞肺癌患者个体化治疗的指导意义［J］.中国老年学杂志，2015，35(02)：387-389.］
[24]Wang Y.Practical gerontology（version 1)［M］.Beijing：People's Health Press，2013：585-587.［汪耀.实用老年病学（第1版）［M］.北京：人民卫生出版社，2013：585-587.］

Memo

Memo:
山东省医药卫生科技发展计划（保健）项目（编号：2015WSCO2042）
Last Update: 2018-12-29